1-Nitro-2-Phenylethane as a Multitarget Candidate for Cognitive and Psychiatric Disorders: Insights from In Silico and Behavioral Approaches
<b>Background/Objectives</b>: Neurological and psychiatric disorders share overlapping mechanisms, such as oxidative stress, neuroinflammation, and neurotransmitter imbalance. In this context, multitarget natural molecules have gained attention. 1-nitro-2-phenylethane (1N2PE), a major constituent of <i>Aniba canelilla</i> essential oil, is known for its antioxidant, anti-inflammatory, and anticholinesterase effects, yet its neuropharmacological profile remains poorly understood. <b>Methods</b>: This study integrated in silico predictions and in vivo behavioral assays to characterize 1N2PE. <b>Results</b>: Pharmacokinetic analyses indicated favorable drug-like properties, with high gastrointestinal absorption, blood-brain barrier penetration, and no P-gp substrate profile. Molecular docking and dynamics revealed stable interactions with dopamine transporter (DAT, ΔG = -26.26 kcal/mol), prostaglandin-H synthase-1 (PGHS-1, ΔG = -20.27 kcal/mol), serotonin transporter (SERT, ΔG = -18.20 kcal/mol), and acetylcholinesterase (AChE, ΔG = -16.58 kcal/mol). In vivo, using a scopolamine-induced impairment model, 1N2PE significantly improved spatial memory and cognition in the Morris water maze. Treated animals reduced the distance to the target zone by ~40% compared with scopolamine-only rats (<i>p</i> < 0.01), normalized latency during training, and exhibited 30% less immobility (<i>p</i> < 0.05), indicating antidepressant-like effects. Moreover, 1N2PE attenuated anxiety-like thigmotaxis, restoring exploratory patterns (<i>p</i> < 0.0001). <b>Conclusions</b>: Together, these findings highlight 1N2PE as a multitarget candidate for cognitive and psychiatric disorders, combining favorable pharmacokinetic properties with preclinical efficacy, warranting further biochemical and translational investigations.
Authors
- Cristiane do Socorro Ferraz Maia (ORCID: https://orcid.org/0000-0003-4493-7375)
- Lucas Villar Pedrosa da Silva Pantoja (ORCID: https://orcid.org/0000-0002-2717-5500)
- Bruno Gonçalves Pinheiro (ORCID: https://orcid.org/0000-0003-1409-4864)
- Enéas Andrade Fontes-Júnior (ORCID: https://orcid.org/0000-0002-6186-9581)
- João Augusto Pereira da Rocha
- Nelson Alencar (ORCID: https://orcid.org/0000-0002-5763-7024)
- Agnaldo Silva Carneiro
- Fábio José Coelho de Souza-Júnior (ORCID: https://orcid.org/0000-0003-3300-8327)
- Daniele Luz de Campos
- Brenda Costa da Conceição
- Jofre Jacob da Silva Freitas (ORCID: https://orcid.org/0000-0002-0568-7177)
- Joyce Kelly R. da Silva (ORCID: https://orcid.org/0000-0002-9351-876X)
- Eduardo Fonseca (ORCID: https://orcid.org/0000-0002-8048-2681)
- Mozaniel Santana de Oliveira (ORCID: https://orcid.org/0000-0002-4076-2443)
- Caroline Araújo Costa de Lima
- José Guilherme S. Maia (ORCID: https://orcid.org/0000-0003-2201-8570)
Institutions
- Universidade do Estado do Pará (BR)
- Instituto Federal de Educação, Ciência e Tecnologia do Pará (BR)
- Universidade Federal do Pará (BR)
Publication Details
- Journal
- Pharmaceuticals
- Published
- 2025-10-09
- DOI
- https://doi.org/10.3390/ph18101511
- Primary Topic
- Neuroscience and Neuropharmacology Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00